A recent study demonstrated that CDCP1 is increased ∼9 fold in chronic myeloid leukemia cells that are resistant to the selective Bcr-Abl kinase inhibitor nilotinib, and that silencing of CDCP1 markedly improved responses to nilotinib [31]. The gene discussed is CDCP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.